Tender detail
Non-exclusive rebate agreement for filgrastim for 2027, with a 12-month extension option
Summary
DAK-Gesundheit and the participating statutory health insurers are seeking non-exclusive pharmaceutical rebate agreements with interested pharmaceutical companies for medicines containing filgrastim (ATC L03AA02). The agreements are scheduled to run from 1 January to 31 December 2027, with an option to extend once for 12 months; they end earlier if an exclusive agreement for the active substance takes effect.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.